[1
]
From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular
Medicine, Brigham and Women's Hospital (S.D.W., M.P.B., T.A.Z., J.F.K., S.A.M., D.L.B.,
C.T.R., M.S.S.), and the Cardiology Division, Massachusetts General Hospital (M.G.S.)
- both in Boston; the Diabetes Unit, Hadassah Hebrew University Hospital, Jerusalem
(I.R., O.M., A.C.); the Department of Cardiovascular Medicine, Kyoto University Graduate
School of Medicine, Kyoto, Japan (E.T.K.); Li Ka Shing Knowledge Institute, St. Michael's
Hospital, University of Toronto, Toronto (L.A.L.); the Division of Cardiology, University
of Texas Southwestern Medical Center, Dallas (D.K.M.); Institute of Ageing and Chronic
Disease, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and AstraZeneca
Gothenburg, Mölndal, Sweden (I.A.M.G.-N., M.F., P.A.J., A.-M.L.).